D. E. Shaw & Co. Inc. Buys 87,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

D. E. Shaw & Co. Inc. lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 80.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 196,319 shares of the specialty pharmaceutical company's stock after acquiring an additional 87,698 shares during the period. D. E. Shaw & Co. Inc. owned 0.93% of ANI Pharmaceuticals worth $10,853,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ANIP. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after acquiring an additional 30,420 shares in the last quarter. Deep Track Capital LP lifted its holdings in shares of ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares during the period. William Blair Investment Management LLC increased its stake in ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after purchasing an additional 10,440 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock worth $23,720,000 after purchasing an additional 3,774 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares in the company, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider now owns 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,681 shares of company stock valued at $468,698 over the last 90 days. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ ANIP traded down $0.45 during midday trading on Tuesday, hitting $59.72. The stock had a trading volume of 44,057 shares, compared to its average volume of 297,795. The firm has a market cap of $1.30 billion, a P/E ratio of -108.76 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company's 50-day simple moving average is $66.85 and its 200 day simple moving average is $60.80.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the previous year, the business earned $0.82 EPS. The business's quarterly revenue was up 43.4% compared to the same quarter last year. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.